Close Menu

NEW YORK – T2 Biosystems announced Wednesday it has regained compliance with the Nasdaq's minimum bid price continued listing requirement. 

In April, the company was notified it wasn't in compliance with the requirement because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.